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Monoclonal Antibodies to Human Transglutaminase 4
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Transglutaminase 4 (TG4) is a member of the enzyme family that catalyzes the calcium-dependent post-translational
modification of proteins via cross-linking, polyamination, or deamidation. TG4 exhibits prostate-specific ex-
pression pattern and plays a crucial role in the formation of the copulatory plug in rodents. However, the
physiological function(s) of human TG4 remains speculative. Human TG4 has been postulated to participate in
the maturation process of sperm by modifying its cell surface, which results in suppression of sperm antigenicity
in the female genital tract. To better understand the pathophysiological role of TG4 in prostate tissue, we
generated monoclonal antibodies (MAb) against human TG4 in mice by repeated injections with the recombi-
nant human TG4. Western blot analysis demonstrated that the selected MAbs react specifically with TG4, but not
with other isoenzymes of the TG family. Immunocytochemical and immunohistochemical analyses showed that
specific staining is observed with the cells overexpressing TG4 and with the paraffin-embedded prostate tissue
specimens obtained from the benign prostate hyperplasia and prostate cancer patients, respectively. Our results
indicate that these MAbs are suitable for detecting TG4 in the cultured cells or prostate tissues for investigating
the biological functions of human TG4.
Introduction
T ransglutaminases (TGs, EC 2.3.2.13) are a family ofcalcium-dependent enzymes that catalyze the post-
translational modification of the selected glutamine residues
on proteins by crosslinking with the peptide-bound lysine
residues or incorporating polyamines.(1) Eight TG isoenzymes
share homology in amino acid sequence, tertiary structure,
and catalytic mechanism, and participate in the protective
functions of cells or tissues by providing a high molecular
weight of protein architecture during skin differentiation,
blood clotting, and wound healing processes.(1)
Although TG activity can be detected throughout the body,
a certain type of TG has distinct tissue distribution, for ex-
ample, TG4 in prostate tissue and seminal fluid.(2–4) TG4
(prostate TG or TGp) was originally characterized as a highly
glycosylated protein enriched in dorsal prostate of rodents.(2,5)
The studies concerning the nature of post-ejeculatory plug
have highlighted the role of TG4 in the reproduction biology
of rodents.(6–8) It has been assumed that the copulatory plug
produced by TG4 facilitates the fertilization by preventing
seminal fluid from leaking out of the vagina.(6) In addition,
TG4 has been considered to conjugate seminal proteins or
polyamines to sperm cell surfaces, which could decrease im-
mune responses against sperm cells in the female genital
tract.(7,8) However, little is known about the physiological
roles of human TG4.
The studies on human TG4 have been limited due to the
lack of available monoclonal antibodies (MAbs) to human
TG4.(9,10) Polyclonal antisera against human TG4 were de-
veloped in a previous report.(4) However, cross-reactivity of
the polyclonal antisera was not fully validated, especially
with other isoenzymes of the TG family. We report that MAbs
against human TG4 newly developed in the present study
bind specifically to human TG4, and thus are applicable to
cytochemical as well as biochemical analyses.
Materials and Methods
Preparation of recombinant human TG4
Full-length cDNA of human TG4 (GenBank accession no.
U31905) was amplified by RT-PCR with RNA from prostate
tissue and cloned into pET-15b vector (Novagen, Madison,
WI). Expression of recombinant human TG4 (rhTG4) was
induced by incubation with 1 mM IPTG for 4 h at 378C in BL21
(DE3) cells. Inclusion body fraction was prepared by repeat-
ing sonication and subsequent centrifugation at 12,000 g for
30 min at 48C, and then solubilized by incubation with de-
naturation buffer (6 M urea, 20 mM Tris [pH 7.9], 500 mM
NaCl, 5 mM imidazole, and protease inhibitor cocktail) for 2 h
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at 258C. After centrifugation at 20,000 g for 30 min at 48C,
rhTG4 was purified by stepwise elution of imidazole in nickel-
nitrilotriacetic acid column according to the manufacturer’s
instructions (Qiagen, Hilden, Germany). The purified protein
was dialyzed against phosphate-buffered saline (PBS) with
decreasing concentration of urea. The protein concentration
was determined by BCA method (Pierce, Rockford, IL), and
its purity was evaluated by 12% SDS-PAGE with Coomassie
Blue staining.
Immunization
Female BALB/c mice (68 weeks old) were injected in-
traperitoneally with 10 mg rhTG4 mixed with an equal volume
of Freund’s complete adjuvant (Sigma, St. Louis, MO). At
10 days after immunization, the serum sample was monitored
for the production of antibodies to rhTG4. Antibody titer was
assessed by enzyme-linked immunosorbent assay (ELISA).
The injection was repeated three times at 3-week intervals
until the antibody titer reached OD490 > 2 at 100-fold dilution
of the mouse serum.
Hybridoma cell cloning
At 3.5 days after the last boost, the splenocytes were fused
with SP2/0-Ag14 mouse myeloma cells in the presence of
polyethylene glycol 1500 (Roche Diagnostics GmbH, Mann-
heim, Germany), as previously described.(11) Hybridoma cells
were subjected to DMEM-HAT selection media (Invitrogen,
Carlsbad, CA) with 20% fetal bovine serum (Hyclone, Logan,
UT) in 96-well cell culture plates. After limiting dilution, the
hybridoma clones exhibiting a high titer to rhTG4 were se-
lected by ELISA.
Antibody purification and isotyping
Pristane-primed female BALB/c mice were injected with
5106 cells of the selected hybridoma. Mouse ascitic fluid was
fractionated by precipitation in 50% saturated ammonium
sulfate. The precipitate was dissolved in PBS, dialyzed against
the same buffer. The dialysate was subjected to a Protein
G-coupled Sepharose 4B (Amersham, Piscataway, NJ) column
chromatography. The antibody concentration was deter-
mined either by BCA method (Pierce) or absorbance mea-
surement at 280 nm. The isotypes of monoclonal antibodies
were determined by solid-phase mouse monoclonal isotyping
kit (Hyclone).
Enzyme-linked immunosorbent assay
A microtiter plate (Nunc, Roskilde, Denmark) was coated
with 1mg/mL rhTG4 in 10 mM Na2CO3 (pH 9.6) buffer for 1 h,
and then over-coated with 3% BSA (Sigma) in PBS for 1 h.
rhTG2 was used as a negative control to validate antibody
specificity.(12) The serum samples, cell culture supernatants,
or purified MAbs were pre-diluted with 1% BSA in PBS
containing Tween-20 (PBST) serially, before adding in tripli-
cate to wells. The reaction was allowed for 1 h, followed by
probing with horseradish peroxidase (HRP)-conjugated sec-
ondary antibody (Sigma) for 1 h. O-phenylenediamine dihy-
drochloride (0.4 mg/mL, Sigma) in citrate-phosphate (0.1 M
citric acid, 0.2 M Na2HPO4) was added for color development,
which was stopped by adding 1 M H2SO4 solution. The ab-
sorbance at 490 nm was measured using a microplate spec-
trophotometer (Molecular Devices, Sunnyvale, CA).
Transfection
Transfection experiments were performed as previously
described.(13). Briefly, NIH3T3 or HeLa cells were plated at
5105 cells per 60-mm dish in DMEM containing 10% fetal
bovine serum and incubated in humidified atmosphere with
5% CO2 at 378C for 16 h. Cells were then transfected with
pcDNA3-TG4 using LipofectAMINE reagent (Invitrogen).
After incubation for 24 h, expression of TG4 was accessed by
Western blot analysis or immunocytochemical method.
Expression of TG isoenyzmes in yeast
cDNAs of five human TGs were cloned into pYES2.0 vector
(Invitrogen). Each TG was tagged with hemagglutinin (HA)
epitope to compare protein expression levels. INVsc1 cells
(Invitrogen) were transformed by lithium acetate/single-
stranded DNA/polyethylglycol method,(14) and the cells
were subjected to SD medium (0.67% yeast nitrogen base
without amino acids, 2% glucose, and 0.065% CSM-URA).
Expression of protein was induced by incubation with YPG
medium (1% yeast extract, 2% bacto-peptone, and 2% galac-
tose). The yeast cell extracts were prepared by glass bead
method.(14) Expression of each enzyme was evaluated by
Western blot analysis using anti-HA antibody (Roche).
Prostate specimens and prostatic fluid collection
Human prostate specimens were obtained from patients
diagnosed to have benign prostate hyperplasia (BPH) or
prostate adenocarcinoma by transurethral resection of pros-
tate or radical prostatectomy, respectively. Prostatic fluid was
collected from the urethra of BPH patients by digital massage.
Western blot analysis
Western blot analysis was performed as previously de-
scribed.(12) Tissue homogenates or fluids were mixed with
Laemmli buffer and resolved by 8% SDS-PAGE. Transferred
membranes were probed by monoclonal antibody (hTG4-
Ma6) and HRP-conjugated anti-mouse IgG antibody (Zymed,
South San Francisco, CA).
Immunostaining with transfected cells
and prostate tissue
HeLa cells transfected with pcDNA3-TG4 were fixed with
4% formaldehyde in PBS for 15 min, and then permeabilized
by treating with 0.1% Triton X-100 in PBS for 5 min at RT.
Prostate tissue specimens prepared on a lysine-coated slide
were incubated in 3% H2O2 solution for 30 min. After treating
with 1% BSA in PBS at RT for 30 min, the cell or tissue spec-
imens were incubated with MAb hTG4-Ma6 in 1% BSA-PBST
for 1 h. The expression of TG4 in the transfected cells or
prostate tissues was probed by incubation with FITC-labeled
anti-mouse antibody (Molecular Probes, Eugene, OR) or with
the secondary antibody (PicturePlus, Zymed), followed
by chromogenic reaction with diaminobenzidine hydrochlo-
ride, respectively. Cells were photographed with LSM 510
META confocal laser-scanning microscope (Zeiss, Oberkochen,
Germany).
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Results and Discussion
Generation of MAbs specific for human TG4
To generate MAbs, full-length human TG4 was produced
using bacterial expression system and purified by affinity
chromatography under denaturing conditions. Partially re-
natured protein was used to immunize BALB/c mice. Fol-
lowing the third injection, the serum samples collected from
all mice showed a higher titer of antibody when tested by
ELISA (>1:104 dilution). The fused hybridoma cells were
cloned by limiting dilution technique and were subsequently
subcloned by measuring the antibody titer. We selected four
hybridomas (hTG4-Ma3, hTG4-Ma6, hTG4-Ma9, and hTG4-
Ma11), which produced MAbs with high titer, showing typ-
ical dilution patterns in solid-phase ELISA. When the isotype
of the MAbs was determined using solid-phase isotyping kit,
the heavy chain of MAbs was IgG2a (hTG4-Ma11) or IgG2b
(hTG4-Ma3, hTG4-Ma6, and hTG4-Ma9). Because four MAbs
gave similar results in ELISA in this study, hTG4-Ma6 was
utilized to demonstrate the specificity and feasibility of im-
munodetection for human TG4.
Specificity of MAbs determined
by Western blot analysis
Specific recognition of human TG4 by hTG4-Ma6 was
evaluated by Western blot analysis. When human TG4 was
FIG. 1. Specificity test of MAb hTG4-Ma6 by Western blot
analysis. (A) NIH 3T3 cells were transfected with pcDNA3 or
pcDNA3-TG4. The cell extracts were resolved in 12% SDS-
PAGE. (B) Five TGs (TG1–4 and factor XIIIa) tagged with
HA epitope were expressed in yeast cells. The yeast cell ex-
tracts were resolved in 8% SDS-PAGE. The expression of TGs
was validated by Western blot analysis using an anti-HA
antibody. (C) Prostate tissue homogenates or prostatic fluids
from BPH patients were resolved in 8% SDS-PAGE. The re-
combinant human TG4 (rhTG4) was used as a positive
control. The proteins in the transferred membrane were
probed with MAb (hTG4-Ma6).
FIG. 2. Immunostaining of HeLa cells expressing TG4 and
prostate tissue specimens with MAb hTG4-Ma6. (A) HeLa
cells were transfected with pcDNA3 (vector, left) or
pcDNA3-TG4 (TG4, right). Cells were fixed, permeabilized,
and incubated with MAb hTG4-Ma6. Cells were probed with
FITC-labeled secondary antibody and visualized with confo-
cal laser scanning microscope. (B, C) Immunohistochemical
staining of prostate tissue specimens. BPH (B) and prostate
cancer (C) tissue specimens were prepared in paraffin blocks.
The specimens were reacted with MAb (hTG4-Ma6) and sec-
ondary antibody. After chromogenic reaction with diamino-
benzidine, the specimens were counterstained with
hematoxylin and photographed.
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transiently expressed in NIH3T3 cells, hTG4-Ma6 reacted
specifically with cells expressing TG4, but not with cells
transfected with control vector (Fig. 1A). No antibody reac-
tivity was found in pre-adsorption experiment with rhTG4
(data not shown). The specificity of hTG4-Ma6 was further
verified by Western blot analysis with a panel of cell lines
(HeLa, MCF7, HEK293, Saos-2, SH-SY5Y, PC-3M, LNCap,
and DU145). This included prostate cancer cells (PC-3M,
LNCap, and DU145) in which no TG4 is known to be ex-
pressed.(15) We found that hTG4-Ma6 did not react with any
cellular proteins of these cell lines, showing specific interac-
tion of hTG4-Ma6 with TG4 (data not shown).
Isoenzymes of the TG family have highly similar amino
acid sequences and conserved structure. We thus examined
whether hTG4-Ma6 could recognize other isoenzymes of the
TG family. Five TGs (TG1–4 and FXIIIa) were produced in
yeast cells as tagged proteins containing HA epitope at
carboxy-terminus. The expression of five TGs was confirmed
by Western blot analysis using anti-HA antibody. hTG4-Ma6
reacted with TG4, and did not react with other TGs (Fig. 1B),
indicating that hTG4-Ma6 specifically recognize TG4.
Western blot analysis of TG4 in prostate tissues
and prostatic fluids
We next examined whether hTG4-Ma6 could react with
TG4 in prostate tissues or prostatic fluid, which are known to
contain TG4.(4) hTG4-Ma6 reacted with TG4 in tissue samples
in Western blot analysis (Fig. 1C). Molecular weight of a major
band detected in tissue samples was estimated to be 75 kDa,
which is similar in size to rhTG4. The expression levels of TG4
in both tissue samples varied among individuals. Smearing
band or a larger size of band (*85 kDa) was detected in some
samples, suggesting a glycosylated TG4 protein.(2,5) A series
of biochemical analyses was needed to understand the nature
of TG4 expressed in or secreted from prostate tissues.
Immunostaining of HeLa cells expressing TG4
and prostate tissue specimens
Application of hTG4-Ma6 in immunostaining was initially
examined with HeLa cells expressing TG4. hTG4-Ma6 was
capable of positively staining the HeLa cells transfected with
TG4 cDNA, and did not stain vector-transfected HeLa cells
(Fig. 2A). We next examined whether hTG4-Ma6 could react
with TG4 protein in the prostate tissues. hTG4-Ma6 positively
stained the paraffin-embedded specimens obtained from pa-
tients with BPH and prostate adenocarcinoma (Fig. 2B, C).
The hTG4-Ma6 positively stained most luminal cells in both
specimens, showing a Golgi-staining pattern, but immuno-
reactivity of hTG4-Ma6 was not detected in stromal com-
partments. The specificity of immunostaining was confirmed
by omitting the incubation step with primary antibody (data
not shown). Thus, these data indicate that hTG4-Ma6 specif-
ically can react with TG4 in tissue specimens and provide an
immunohistochemical tool to study TG4 in the prostate tissue.
In this study, we generated and characterized MAbs to
human TG4. We were able to produce antibodies in high titer in
mice, as judged by ELISA, by repeated injection of the recom-
binant TG4 derived from bacterial expression system. The
selected MAb specifically binds to TG4, showing no cross-
reactivity with other types of TGs. We showed that the MAb
could be applicable to immunostaining of cultured cells or
prostate tissues as well as Western blot analysis. We also have
observed that the binding of MAb to TG4 did not interfere with
its activity (data not shown), suggesting that the MAb is ap-
plicable to immunocomplex assays for monitoring TG4 activ-
ity. In addition, TG4 was able to be depleted in clinical samples
by applying the MAbs, which allow us to evaluate a portion of
TG4 activity among total TG activities. However, a relatively
large amount of MAb was needed for immunoprecipitation.
Interestingly, partially heat-denatured TG4 was more effec-
tively precipitated than native TG4 (data not shown), probably
because denatured TG4 was used as an immunogen.
TG4 has been assumed to play a crucial role in suppressing
antigenicity of sperm cells in female genital tract.(7,8) Inter-
estingly, ejaculated sperm cells are not immunogenic com-
pared to epididymal spermatozoon, indicating that sperm
maturation is an important process to prevent immune re-
jection in the genital tract. The role of TG4 in sperm matura-
tion has also been supported by circumstantial evidence that
semen has many kinds of TG substrates and high concentra-
tion of polyamines, which can be incorporated into sperm cell
surfaces by TG4.(7,8) Thus, TG4 activity may be linked to
sperm cell behaviors, which may provide insight into the
etiology of infertility. Nonetheless, so far the physiological
roles of TG4 in humans have been of little concern. Our MAbs
may be a useful tool for investigation, delineating the roles of
TG4 in reproduction biology.
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